An integrated analysis of nine trials in the Phase II and III stages assessed glecaprevir and pibrentasvir as a treatment for chronic hepatitis C genotype 1 to 6 infections and indicated that the regimen was safe and effective in those with compensated liver disease as well as those with stage IV or stage V chronic kidney disease. Details of the analysis were published in the journal Clinical Infectious Diseases.
Glecaprevir, pibrentasvir effective in those with HCV, liver disease
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.